Lyra Therapeutics (LYRA) Retained Earnings (2019 - 2025)
Quarterly Retained Earnings fell 7.14% to -$433.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$433.7 million through Dec 2025, down 7.14% year-over-year, with the annual reading at -$433.7 million for FY2025, 7.14% down from the prior year.
Lyra Therapeutics' Retained Earnings history spans 7 years, with the latest figure at -$433.7 million for Q4 2025.
- Retained Earnings came in at -$433.7 million for Q4 2025, down from -$426.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$4000.0 in Q2 2024 to a low of -$433.7 million in Q4 2025.
- The 5-year median for Retained Earnings is -$264.6 million (2022), against an average of -$266.1 million.
- Year-over-year, Retained Earnings soared 100.0% in 2024 and then tumbled 10519250.0% in 2025.
- Lyra Therapeutics' Retained Earnings stood at -$193.4 million in 2021, then fell by 28.58% to -$248.7 million in 2022, then decreased by 25.21% to -$311.4 million in 2023, then tumbled by 30.01% to -$404.8 million in 2024, then dropped by 7.14% to -$433.7 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Retained Earnings are -$433.7 million (Q4 2025), -$426.8 million (Q3 2025), and -$420.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 36.42 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 130.89 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Lyra Therapeutics | - | - | - | -433.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -433.71 Mn |
| Sep 30, 2025 | -426.76 Mn |
| Jun 30, 2025 | -420.77 Mn |
| Mar 31, 2025 | -413.34 Mn |
| Dec 31, 2024 | -404.79 Mn |
| Sep 30, 2024 | -393.80 Mn |
| Jun 30, 2024 | -4,000.00 |
| Mar 31, 2024 | -333.81 Mn |
| Dec 31, 2023 | -311.36 Mn |
| Sep 30, 2023 | -296.20 Mn |
| Jun 30, 2023 | -280.55 Mn |
| Mar 31, 2023 | -12,000.00 |
| Dec 31, 2022 | -248.68 Mn |
| Sep 30, 2022 | -234.44 Mn |
| Jun 30, 2022 | -219.70 Mn |
| Mar 31, 2022 | -205.30 Mn |
| Dec 31, 2021 | -193.40 Mn |
| Sep 30, 2021 | -179.80 Mn |
| Jun 30, 2021 | -168.73 Mn |
| Mar 31, 2021 | -157.69 Mn |
| Dec 31, 2020 | -149.88 Mn |
| Sep 30, 2020 | -142.86 Mn |
| Jun 30, 2020 | -136.53 Mn |
| Mar 31, 2020 | -131.99 Mn |
| Dec 31, 2019 | -127.76 Mn |